AI products from Cadence and Limbic are among four devices recently accepted into the FDA’s TEMPO pilot that will allow digital health companies to release products without marketing authorization.
AI products from Cadence and Limbic are among four devices recently accepted into the FDA’s TEMPO pilot that will allow digital health companies to release products without marketing authorization.
<iframe src="https://statesidedaily.com/embed/cluster/f9bcabd4a23b9d79b22ab59a6dd38ea529094cd0" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized"></iframe>
